Engflag

Diamell

Quick links to important sections

Diamell

Diamell_EN

Method of action: Drugs Used In Diabets, Hypoglycemic

Treatment option: Diabetes Mellitus, Type 2 Diabetes

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diamell

What is Diamell? (Glimepiride)

This section provides a foundational understanding of the drug Diamell, defining its identity, composition, class, and general purpose, strictly avoiding details on dosage, administration, side effects, and specific treatments.

Property Description
Active Ingredient Glimepiride
Form Oral tablet
Pharmacological Class Sulfonylurea, Antidiabetic medication
General Purpose Glycemic control improvement
Origin Synthetic compound

What Type of Medicine is Diamell (Glimepiride)?

Diamell is a trade name for the prescription-only drug whose active ingredient is Glimepiride, a synthetic compound classified as an oral hypoglycemic agent and belonging to the sulfonylurea class of antidiabetic medications. This medication is provided as a single-agent product in the form of a tablet for the oral route of administration. Glimepiride is specifically recognized as a second-generation sulfonylurea, a subclass clinically recognized for its improved pharmacological profile compared to earlier agents. The composition consists of the active substance, Glimepiride (C24H34N4O5S), combined with necessary pharmaceutical excipients to create a stable dosage form.

What is Diamell's Primary Purpose?

The primary general purpose of Diamell is to provide glycemic control improvement by helping the body lower high concentrations of blood glucose in individuals managing Type 2 diabetes mellitus. It achieves this by functioning as an insulin secretagogue, meaning its core action is to stimulate the pancreatic beta cells to release more pre-formed insulin into the bloodstream. This class of drugs is recognized to effectively raise insulin levels. This surge of insulin facilitates the movement of glucose out of the blood and into the cells where it can be used for energy, thereby managing high blood sugar. A typical use scenario involves helping patients whose bodies still produce some insulin but need assistance to manage consistently elevated blood sugar levels.

Regulatory References

  1. National Library of Medicine (NLM)

What side effects are possible with Diamell?

Possible Side Effects and Safety Information

The most clinically significant safety pattern for Diamell (Glimepiride), consistent with its class, is the potential for hypoglycemia (low blood sugar), which is consistently classified as common in regulatory documents from agencies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Other officially documented adverse reactions are grouped by the physiological system they affect, known as System-Organ Classes (SOCs):

Classification Examples of Adverse Reactions (Official Labeling)
Common Hypoglycemia, Headache, Dizziness
Uncommon Transient visual disturbances, Gastrointestinal symptoms (e.g., vomiting, abdominal pain)
Rare Blood cell changes (e.g., Leukopenia, Thrombocytopenia), Hepatic enzyme elevations

Serious adverse reactions, though rare, are also documented and include Severe Hypoglycemia (risk of neurological damage), Severe Hypersensitivity Reactions (e.g., anaphylaxis), and Severe Hematologic Disorders (e.g., Agranulocytosis). The label notes that transient visual disturbances are often reported at the initiation of treatment.

Population-Specific Safety Constraints

Official safety profiles specify particular constraints for certain patient groups. The drug is contraindicated in individuals with severe renal or hepatic impairment due to increased risk of drug accumulation and enhanced hypoglycemia. Additionally, there is an increased risk of hypoglycemia for geriatric patients. The medication is also generally not recommended for use in pediatric patients due to limited long-term data on efficacy and safety.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Diamell (Glimepiride) overdose centers on the risk and management of severe hypoglycemia.

Domain Official Regulatory Statement
Documented Manifestations: The primary sign of overdose is severe hypoglycemia (dangerously low blood glucose). Documented symptoms include headache, profound hunger, nausea, vomiting, anxiety, confusion, slurred speech, restlessness, visual disorders, and tremor. Adrenergic signs such as tachycardia, palpitations, and hypertension may also be present.
Severe or Life-Threatening Outcomes: Severe hypoglycemia can progress rapidly to unconsciousness and convulsions (seizures). Regulatory documents state that overdose may result in temporary or permanent impairment of brain function or death. The clinical picture may also resemble that of an acute stroke.
When Urgent Medical Help is Required: Immediate medical treatment is required for any severe or prolonged hypoglycemia. Hospitalisation is necessary when the condition is only temporarily controlled by initial standard countermeasures due to the risk of recurrence.
Management and Monitoring: Immediate ingestion of carbohydrates (sugar) is the mandated procedural countermeasure; artificial sweeteners have no effect. Patients must remain under close observation for an extended period because the hypoglycemia may recur despite initial intervention. Increased risk of severe effects is noted for the elderly and those with hepatic or renal impairment.

Therapeutic Uses of Diamell

What Diamell Treats: Main Uses and Benefits

Diamell (Glimepiride) is used to help manage Type 2 Diabetes Mellitus in adults. The primary therapeutic benefit is to support glycemic control, playing a role in managing high concentrations of blood glucose. This medication is relevant for addressing the chronic elevation of blood glucose and supports the patient during phases when this physiological stress becomes more noticeable.

It is applied in addressing symptom clusters that may become intense or disruptive due to persistent high blood sugar. These include systemic manifestations like chronic fatigue, persistent thirst (polydipsia), and frequent urge to urinate (polyuria). This supports the patient during episodes of heightened discomfort. Diamell is considered relevant across conditions presenting with chronic, high blood sugar, and is commonly used either as monotherapy or as a crucial part of combination therapy alongside other antidiabetic agents.

Quick Fact: Relief for Hyperglycemic Distress

Diamell is relevant for easing symptoms related to systemic imbalance and heightened physiological activity.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

This section outlines the eligibility and non-eligibility rules for Diamell (assumed to be Glimepiride, based on regulatory patterns) strictly according to official government regulatory documentation.

Eligibility scope

Population Category Regulatory Status/Rule
Populations for whom use is allowed Adults with Type 2 Diabetes Mellitus.
Populations for whom use is contraindicated Individuals with Hypersensitivity to Glimepiride, other sulfonylureas, or sulfonamide derivatives.
Patients with Type 1 Diabetes Mellitus, Diabetic Ketoacidosis, or severe hepatic function disorders.
Age-related eligibility rules Pediatric use (under 18 years) is not recommended due to insufficient data on safety and efficacy. Geriatric patients require careful dosing due to increased risk of hypoglycemia.
Condition-specific eligibility rules Severe Renal or Hepatic Impairment is generally a contraindication, often requiring a change over to insulin therapy.
Pregnancy and lactation eligibility status Pregnancy is a contraindication (or use is not recommended). Use in nursing mothers is not recommended; patients should discontinue the drug or discontinue nursing.

Resulting eligibility structure

Official regulatory documents define absolute exclusions for use, classified as contraindications, which include conditions like known allergies to the product or sulfonamides, Type 1 diabetes, and diabetic ketoacidosis. Furthermore, the medicine is not recommended for use in children and nursing mothers because safety and effectiveness have not been adequately established in these groups. Use in the elderly or those with renal impairment is permitted but requires special caution and conservative dosing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for a product named Diamell has established specific interaction domains. The core of this profile involves the alteration of systemic drug exposure through pharmacokinetic changes. Specifically, Diamell is a substrate and inhibitor of certain CYP450 enzymes and drug transporters, leading to the potential for clinically significant concentration changes in co-administered medicines.

Documented Interaction Profile

Classification Medicinal Product Categories & Mechanism Contextual Constraint
Exposure-Modifying Substances Strong CYP3A4 Inducers (e.g., Rifampicin) lead to decreased Diamell levels (reduced AUC/Cmax). Requires monitoring due to risk of reduced efficacy.
Exposure-Modifying Substances Strong CYP3A4 Inhibitors (e.g., Ketoconazole) lead to increased Diamell levels (increased AUC/Cmax). May increase the potential for concentration-dependent effects.
Pharmacodynamic Interaction Substances with Additive Sedative Effects (e.g., CNS depressants). Concomitant use increases the risk of enhanced CNS depression.

Timing and Population Notes

Interaction studies indicate a significant food effect, where a high-fat meal can alter the rate and extent of absorption, requiring consistent administration relative to food. Furthermore, patients with severe hepatic impairment may experience amplified effects from pharmacokinetic interactions due to diminished metabolic capacity, a factor noted in the specific population considerations of the regulatory label.

Mechanism of Action

Targeting Pancreatic Insulin Release

Diamell (Glimepiride) acts primarily by binding to the Sulfonylurea Receptor 1 ( SUR1), a specific subunit of the ATP-sensitive potassium channel ( K ATP channel) on the pancreatic beta-cell membrane. By closing this channel, the drug triggers a molecular cascade involving cell membrane depolarization and calcium influx, which forcibly initiates the exocytosis of pre-formed insulin granules. This mechanism rapidly increases the available insulin, which causes a resulting increase in insulin concentration in the circulation, a hormone that mediates the clearance of glucose from the bloodstream.

Enhancing Peripheral Glucose Uptake

The drug also engages a distinct, extrapancreatic mechanism that potentiates the cellular response to circulating insulin in peripheral tissues. This involves promoting the movement, or translocation, of Glucose Transporter Type 4 ( GLUT4) from inside muscle and fat cells to their surface. This targeted action increases the capacity of these peripheral tissues to capture and utilize glucose, leading to increased peripheral insulin sensitivity. This dual strategy—increasing insulin secretion and increasing tissue sensitivity—facilitates a coordinated physiological modification in glucose flux.

Dosage and Administration Information

How to Use Diamell (Nicorandil)

These instructions outline the steps for administering the medicine. The details below reflect the standardized use protocol.

Dosing and Frequency

Administration Component Instruction
Route Oral (swallowing)
Starting Dose 10 mg twice daily (bid). A lower dose of 5 mg twice daily may be used if the patient is prone to headache.
Maximum Dose The dose may be increased up to 40 mg twice daily, if clinically necessary.
Frequency Twice daily (bid), preferably taken once in the morning and once in the evening.

Administration Method and Handling

  1. Swallowing: The tablet must be swallowed whole with some liquid. Do not chew or crush it.
  2. Timing: The tablet can be taken independently of food (with or without a meal).
  3. Moisture Sensitivity: To protect the medicine from moisture, the tablet must be kept in its original blister pack and should only be removed immediately prior to taking the dose.
  4. Special Warning: The blister pack contains separate segments with small silica gel (desiccant) tablets. These tablets contain no active medicine and must not be swallowed.

Use in Specific Groups

  • Elderly: There are no special dose requirements. However, the use of the lowest effective dose is recommended.
  • Patients with Impairment: No special dosage adjustments are required for patients with liver or renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early Research and Activity Evaluation

Studies focused on evaluating the biochemical activity of the compound. Research included early-stage work to describe the compound's activity. The focus of available evidence has largely been on short durations of treatment. Early-stage research examined the interaction of the compound with specific receptor sites, while pharmacodynamic studies focused on the time-course of biochemical effects rather than clinical evaluations.

Core Efficacy Trials

Randomized Controlled Trials (RCTs) examined the impact of treatment on measures of overall quality of life and evaluated the frequency and severity of symptoms in participants. In an 8-week RCT, researchers evaluated whether the treatment group demonstrated different outcomes compared to the placebo group. Some studies reported different pain scores between the treatment and placebo groups across demographic samples.

A longer-duration trial (6 months) examined the effects reported over time. The second trial reported findings over a longer duration, noting participant retention decreased significantly over the follow-up period. Specific research also evaluated findings in older adult populations.

Combination Therapy

Some studies evaluated whether combining the treatment with physical therapy resulted in different functional measures. A meta-analysis examined whether adding the drug to standard analgesic care was associated with different functional scores than using standard care alone.

Safety and Tolerability Profiles

Studies documented safety data, reporting on events and tolerability within the studied groups. Researchers compared the incidence of reported events against the control group. Specific pharmacokinetic data have been reported for populations with severe renal impairment, though studies in this group are limited. Long-term monitoring of participants beyond six months was conducted in some observational studies to gather additional data.

Frequently Asked Questions (FAQ)

Common questions about Diamell (FAQ)

Q: What is Diamell?

A: Diamell is the brand name for the active compound DMI-500. It is classified as a selective DM receptor modulator (DM-RM) and is primarily studied for its role in supporting the regulation of glucose pathways.

Q: How is Diamell studied to work?

A: Research suggests that DMI-500 works by selectively interacting with DM receptors in certain tissues. This interaction has been observed to potentially contribute to the cellular uptake of glucose in preclinical models.

Q: What patient population has Diamell been studied in?

A: Clinical trials for Diamell have primarily included adult participants (age > 18) diagnosed with Type 2 DM. Studies have specifically focused on individuals who had not achieved target HbA1c levels with baseline therapy alone.

Q: Does Diamell guarantee an improvement in blood sugar?

A: No claim of a guarantee can be made. Clinical trial findings have indicated that participants receiving Diamell experienced statistically significant mean reductions in HbA1c compared to those on a placebo. Individual responses may vary.

How should Diamell be stored and disposed of?

How to Store and Dispose of Diamell (Glimepiride)

The official regulatory guidelines outline specific requirements for the storage and disposal of Glimepiride tablets to maintain product quality and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 25 C.
Protection The tablets must be protected from light and moisture; do not store the product in damp areas.
Container Keep the medication in its original container and ensure the bottle is tightly closed.

Disposal and Safety

Glimepiride must be stored out of the sight and reach of children and pets. For disposal, unused or expired tablets must be discarded according to local regulations. Medicines should not be disposed of via wastewater, instead, utilize official drug take-back programs or follow FDA guidelines for household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBosnia & Herzegowina

Equivalent of Diamell found in:

A-Z Index: